Literature DB >> 20934550

Dronedarone and vitamin K antagonists: a review of drug-drug interactions.

Shailesh C Shirolkar1, Mona Fiuzat, Richard C Becker.   

Abstract

Adverse drug events affect millions of patients each year. An important drug-drug interaction between amiodarone and vitamin K antagonists is encountered frequently in daily clinical practice. Warfarin, a commonly used anticoagulant, is a mixture of 2 optically active isomers (R and S enantiomers). The S enantiomer is approximately 3 times more potent than the R enantiomer and is metabolized primarily by CYP2C9. Inhibition of CYP2C9 by amiodarone and its major metabolite potentiates the anticoagulant effects of warfarin, increasing the risk of serious bleeding. In contrast, dronedarone, a synthetic derivative of amiodarone the structure of which lacks the iodine moiety, is less likely to cause a drug-drug interaction with warfarin. Accordingly, dronedarone may be a particularly attractive antiarrhythmic choice among patients with atrial fibrillation who are also being treated with warfarin.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20934550     DOI: 10.1016/j.ahj.2010.07.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Pharmacotherapy of heart failure in the elderly: adverse events.

Authors:  Michael W Rich
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Update on the management of atrial fibrillation: anticoagulation and medical therapy.

Authors:  Shueh Hao Lim; Hugh Calkins; Sunil K Sinha
Journal:  Curr Cardiol Rep       Date:  2011-10       Impact factor: 2.931

3.  Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.

Authors:  Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez
Journal:  Clin Med Insights Cardiol       Date:  2011-10-06

Review 4.  Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.

Authors:  Neil S Roskell; Miny Samuel; Herbert Noack; Brigitta U Monz
Journal:  Europace       Date:  2013-02-13       Impact factor: 5.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.